GSK-971086

GSK-971086
Clinical data
Drug class	Selective androgen receptor modulator
Identifiers
	IUPAC name 2-methyl-4-(trifluoromethyl)-1-[[5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]methyl]indole-5-carbonitrile;
CAS Number	1018971-95-3;
PubChem CID	86620664;
ChemSpider	129433018;
UNII	8TFL50092H;
Chemical and physical data
Formula	C21H12F6N4O
Molar mass	450.344 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC2=C(N1CC3=NOC(=N3)C4=CC(=CC=C4)C(F)(F)F)C=CC(=C2C(F)(F)F)C#N;
	InChI InChI=1S/C21H12F6N4O/c1-11-7-15-16(6-5-13(9-28)18(15)21(25,26)27)31(11)10-17-29-19(32-30-17)12-3-2-4-14(8-12)20(22,23)24/h2-8H,10H2,1H3; Key:ZEDODTZELVBHTG-UHFFFAOYSA-N;

GSK-971086 is an investigational new drug that is a selective androgen receptor modulator (SARM) that was being developed by GlaxoSmithKline (GSK) for the potential treatment of sarcopenia.^[1]^[2] As a SARM, GSK-971086 was designed to target androgen receptors in specific tissues, potentially offering therapeutic benefits for muscle wasting conditions while minimizing unwanted androgenic side effects. The compound underwent early-stage clinical trials to evaluate its safety, tolerability, and pharmacokinetic profile in human subjects.^[3]

Related Articles